Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Outpatient Service for Mid-trimester Termination of Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03346629
Recruitment Status : Completed
First Posted : November 17, 2017
Last Update Posted : April 26, 2019
Sponsor:
Collaborators:
CREHPA
Kathmandu Medical College and Teaching Hospital
Kathmandu Model Hospital
KIST Medical College
Information provided by (Responsible Party):
Gynuity Health Projects

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study seeks to evaluate the safety, acceptability and feasibility of an outpatient "day procedure" for medical abortion at 13-18 weeks gestation. The study regimen will consist of a single dose of 200 mg mifepristone to be taken orally either at home or at the hospital, followed approximately 24 - 48 hours later with administration of 400 mcg misoprostol. Repeat doses of 400 mcg (two tablets) of misoprostol will be administered buccally every three hours until the abortion is achieved.

Condition or disease Intervention/treatment Phase
Abortion in Second Trimester Drug: Mifepristone + Misoprostol Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 230 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluating the Safety, Acceptability and Feasibility of an Outpatient "Day Procedure" Service Documenting the Roles of Health Workers in the Provision of Medical Abortion at 13-18 Weeks Gestation
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Mifepristone + Misoprostol
Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
 Drug: Mifepristone + Misoprostol
A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Successful medical abortion [ Time Frame: 0 - 48 hours after first dose of mifepristone ]
    Proportion of women who have a successful medical abortion without recourse to surgical intervention and return home on the same day as misoprostol induction


Secondary Outcome Measures :
  1. Induction-to-abortion interval [ Time Frame: 0 - 48 hours after first misoprostol dose ]
    Median time elapsed between administration of the first misoprostol dose until expulsion of both fetus and placenta

  2. Total dose of misoprostol [ Time Frame: 0 - 48 hours after first misoprostol dose ]
    Average number of doses of misoprostol

  3. Safety - Proportion of participants who experience at least one of the following: extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, prolonged hospitalization, any complications [ Time Frame: 2 weeks after initial visit ]
    Proportion of participants who experience at least one of the following: extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, prolonged hospitalization, any complications

  4. Tasks performed by certified staff [ Time Frame: 0 - 72 hours after receipt of mifepristone ]
    Type of task performed (i.e. counseling, monitoring vital signs, administering drugs, monitoring woman's condition, post-abortion contraception, managing discharge)

  5. Hospital admission time [ Time Frame: Within 0 - 48 hours after the second dose of misoprostol ]
    Average total hospital admission time

  6. Side Effects [ Time Frame: 0 - 48 hours after first dose of misoprostol ]
    Proportion of participants experiencing side effects (severity incidence, and severity of pain based on a 0-10 point scale)

  7. Initiation-to-abortion interval [ Time Frame: 0 - 72 hours after receipt of mifepristone ]
    Median time elapsed between administration of the mifepristone dose until expulsion of both fetus and placenta


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Have an ongoing pregnancy of 13-18 weeks gestation
  • Meet legal criteria to obtain an abortion at 13-18 weeks gestation (legal criteria include pregnancy resulting from rape or incest, fetal malformation and/or if the pregnancy affects the physical or mental health of the woman)
  • Has access to a phone where she can be reached at the 2-week follow-up
  • Be willing to follow study procedures

Exclusion Criteria:

  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Any contraindications to vaginal delivery
  • More than one prior cesarean delivery
  • Living more than 2 hours away from the hospital
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03346629


Locations
Layout table for location information
Nepal
KIST Medical College, Teaching Hospital
Imadol, Lalitpur, Nepal
Kathmandu Medical College
Kathmandu, Nepal
Kathmandu Model Hospital
Kathmandu, Nepal
Sponsors and Collaborators
Gynuity Health Projects
CREHPA
Kathmandu Medical College and Teaching Hospital
Kathmandu Model Hospital
KIST Medical College
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Blum, MPH Gynuity Health Projects
Principal Investigator: Monica Dragoman, MD, MPH Gynuity Health Projects
Principal Investigator: Chanda Karki, MD Kathmandu Medical College
Principal Investigator: Dina Abbas, MPH Gynuity Health Projects
Principal Investigator: Beverly Winikoff, MD, MPH Gynuity Health Projects
Principal Investigator: Anand Tamang, MPhil CREHPA
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Gynuity Health Projects
ClinicalTrials.gov Identifier: NCT03346629     History of Changes
Other Study ID Numbers: 1039
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Misoprostol
Mifepristone
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics
Abortifacient Agents, Steroidal
 Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents